A Comparison of Cardiovascular Benefits of Dapagliflozin and Empagliflozin in Type 2 Diabetes: A Systematic Review and Meta-analysis

N. BenjaminAarushi GuptaTawfiq TurjmanWajih SyedAnand AnghanChenny KoodarathNaseem SalahuddinMohammed M. KhawarAnirudh Y. EduPiere Ray Tito Rodriguez2026-03-222026-03-22202510.1007/s42399-025-02103-yhttps://doi.org/10.1007/s42399-025-02103-yhttps://andeanlibrary.org/handle/123456789/78036enDapagliflozinEmpagliflozinMedicineInternal medicineDiabetes mellitusType 2 diabetesHeart failureMyocardial infarctionPopulationStroke (engine)A Comparison of Cardiovascular Benefits of Dapagliflozin and Empagliflozin in Type 2 Diabetes: A Systematic Review and Meta-analysisarticle